Hepatitis C News Ticker: Following response-guided therapy guidelines with boceprevir and telaprevir

"Reading the Paper" Lynne Crumpacker

Hepatitis Journal Options – Volume 5, Issue 1

Now Available! CCO Hepatology inPractice™

This special edition includes all the pivotal phase III studies of the HCV protease inhibitors, with a range of commentaries exploring key aspects of the use of these agents, plus Capsule Summaries of each study and downloadable slidesets.

Topics include:

• Following response-guided therapy guidelines with boceprevir and telaprevir
• Understanding futility rules and their importance
• Outcomes and management of anemia
• Strategies for managing telaprevir rash and anorectal symptoms
• Using boceprevir and telaprevir in patients with advanced fibrosis or cirrhosis
• Effect of telaprevir on cyclosporine and tacrolimus pharmacokinetics
• Antiviral activity with telaprevir in patients with genotype 2 or 3 HCV
• Evaluation of HBV screening cost effectiveness

*Free Registration Required-Register Here